BioPharma Drug Approval

Takeda and Zuellig Pharma Partner to Expand Medicine Access Across Three Southeast Asian Markets

Takeda and Zuellig Pharma announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutio...

 November 18, 2026 | News

China’s NMPA Accepts Akeso’s Ivonescimab Application for First-Line Biliary Tract Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accepted the supplemental ...

 November 18, 2026 | News

2026 Drug Approvals: How the FDA, China, Japan and Europe Compare

For most of the last two decades, a year in drug approvals could be summarised in a single number: how many new molecular entities the US Food and Drug Adm...

 November 17, 2026 | Analysis

IDEAYA Nominates IDE101 as Development Candidate for CDKN2A-Deficient Solid Tumours

Development candidate demonstrates encouraging preclinical activity in CDKN2A-deficienct tumor models as a monotherapy and in combi...

 November 17, 2026 | News

FDA Breakthrough Therapy Designation 2026: Three APAC-Originated Drugs Made the List, and None of Them Came From China

The record, counted to 14 November 2026. Method What counts An FDA Breakthrough Therapy designation disclosed by the sponsor or a licensee i...

 November 16, 2026 | Analysis

Neobe Therapeutics Raises US$6.8 Million to Advance Engineered Bacteria for Solid Tumours

 Neobe has secured a seed round of US$6.8 million (£5 million) to accelerate the development of engineered bacteria that break down the physical...

 November 11, 2026 | News

Pierre Fabre and XtalPi Partner on AI-Driven Oncology Drug Discovery

Laboratoires Pierre Fabre and XtalPi (XtalPi Holdings Limited, 2228.HK) are pleased to announce an agreement under which they will collaborate on the disco...

 November 11, 2026 | News

China Accepts Lynk Pharmaceuticals’ Zemprocitinib Filing for Rheumatoid Arthritis

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

 November 09, 2026 | News

VS Pharmtech Advances Radiotherapy Enhancer VS-101 to Phase 2 in the US

Cancer drugs keep improving, but their limits remain. When antibody therapies first emerged, only a fraction of patients benefited, and small-molecule anti...

 November 09, 2026 | News

Brise Pharmaceuticals and AbbVie Advance Migraine Drug Collaboration Worth Up to $757 Million

Brise Pharmaceuticals Co., Ltd. provided an update on its exclusive license agreement with AbbVie (NYSE: ABBV), which the companies entered in 2024. Under ...

 November 04, 2026 | News

China's 2026 Reimbursement Lists: 10 Drugs That Will Show Where Beijing Is Paying, and the Commercial List's Second Year

Where things stand. As of 2 November 2026, the National Healthcare Security Administration (NHSA) has not published the 2026 National Reimbursement Drug Li...

 November 03, 2026 | Regulatory

APAC-Originated Obesity Drugs in the Clinic, Beyond Semaglutide

Obesity was the most searched therapeutic area of 2026, and for most readers the story still has two names in it. Semaglutide and tirzepatide set the bench...

 November 02, 2026 | Analysis

Lynk Pharma’s Zemprocitinib Sustains Strong Rheumatoid Arthritis Responses Through 76 Weeks in Phase III Trial

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases,&...

 October 30, 2026 | News

Lynk Pharmaceuticals Reports Sustained Phase III Efficacy of Zemprocitinib in Rheumatoid Arthritis Through Week 76

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

 October 29, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close